Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty

Feb 1, 2019The Knee

Comparing medicines to prevent blood clots after total knee replacement

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Of 30,813 patients, 1.82% were diagnosed with venous thromboembolism (VTE) after total knee arthroplasty.

Lower risk of VTE was associated with low molecular weight heparin (LMWH), factor Xa inhibitors (XaI), and fondaparinux compared to aspirin.
The odds of VTE were significantly reduced with LMWH (OR 0.47), XaI (OR 0.50), and fondaparinux (OR 0.32).
Higher rates of blood transfusion were linked to LMWH (OR 1.56) and fondaparinux (OR 1.84), indicating increased bleeding risks.
There was no significant difference in hematoma rates across the different anticoagulant medications.
The results suggest that the choice of anticoagulant should consider the balance between VTE prevention and bleeding-related complications.

AI simplified

BACKGROUND: Anticoagulants are used following total knee arthroplasty (TKA) to prevent venous thromboembolism (VTE). These drugs reduce VTE risk but may lead to bleeding-related complications. Recently, surgeons have advocated using antiplatelet agents including aspirin (ASA). However, there is no consensus regarding which medication has the optimal risk/benefit profile. The purpose of this study was to compare rates of VTE using different anticoagulants in anticoagulation-naïve patients being discharged home after TKA.

METHODS: A national private insurance database was used to identify patients undergoing unilateral TKA. Patients with a prior history of VTE were excluded. Anticoagulants included ASA, low molecular weight heparin (LMWH), warfarin, factor Xa inhibitors (XaI), and fondaparinux. Postoperative complications, including VTE, blood transfusion, myocardial infarction, and hematoma, were identified using ICD-9 diagnosis codes. Risk of each complication was compared between groups using multivariate logistic regression controlling for demographics, length of stay, and comorbidities.

RESULTS: Of 30,813 patients, 1.82% were diagnosed with VTE. Using ASA as a baseline, there was significantly decreased risk of VTE with LMWH (OR 0.47), XaI (OR 0.50), and fondaparinux (OR 0.32). There was significantly higher risk of transfusion with LMWH (OR 1.56) and fondaparinux (OR 1.84), but no difference in hematoma between medications.

CONCLUSIONS: This study shows that there is a decreased risk of VTE with LMWH, XaI, and fondaparinux compared to ASA. However, these medications also had higher rates of bleeding-associated complications. The choice of pharmacologic prophylaxis should be made based on a balance of the risk/benefit profile of each medication.

LEVEL OF EVIDENCE: III.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Comparison of pharmacologic prophylaxis in prevention of venous thromboembolism following total knee arthroplasty

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief